Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials.
作者信息
Eichacker Peter Q, Natanson Charles
机构信息
Critical Care Medicine Department, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA.
出版信息
Crit Care Med. 2003 Jan;31(1 Suppl):S94-6. doi: 10.1097/00003246-200301001-00013.
Abstract
摘要
Zotero 插件